VEN 307
Phase 3Small molecule
VEN 307 is one of 17 small molecule programs targeting Anal fissure. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Anal Fissure
#DrugCompanyPhaseTrials
1Golytely
BayerApproved
Isordil
AstraZenecaApproved
Chronulac
SSolvay Pharmaceuticals
Approved
Nitrostat
VViatris Specialty LLC
Phase 3
Carafate
AbbViePhase 2
Cardizem
BBausch Health Americas, Inc.
Phase 2
Centella
UUniversity of Roma La Sapienza
Approved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Imdur
OOmnivium
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VEN 307. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- VVentrus Biosciences, Inc